CN1303934A - Novel polypeptide-human Ra1BPI related protein 82 and polynucleotide coding said polypeptide - Google Patents

Abstract

The present invention discloses a novel polypeptide-human RaIBPI related protein 82, polynucleotide coding said polypeptide and its method for producing said polypeptide by using DNA recombination technology. Said invention also discloses the method for curing several diseases, such as malignant tumor, blood disease, HIV infection, immunological disease and various inflammations by using said polypeptide, and also discloses an antagonist resisting said polypeptide and its therapeutic effect, and also discloses the application of polynucleotide for coding this novel human RaIBPI related protein 82.

Description

A kind of new polypeptide-human Ra1BP1 related protein 82 and the polynucleotide of this peptide species of coding

The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide-human Ra1BP1 related protein 82, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.

Ra1-GTPase, Ra1A, Ra1B has constituted Ras correlative GTP bindin family.The same with all GTPase, Ra1 albumen with show activity after GTP combines, with show activity not after GDP combines.The proteic activation of Ra1 with itself and-interaction of kind of guanosine-exchange factor is relevant, Ra1 mainly plays the effect of regulation and control GTP level in born of the same parents, and GTP provides the energy derive of all biological activities.(The?Journal?OFBiological?Chemistry?1997?Vol272；No50；Dec12?31230-31234)

Ra1BP1 (also claiming RLIP or RLP) is proved to be and can be incorporated into activatory GTP-Ra1 albumen, influences the proteic expression of Ra1, and it is the GAP of CDC42/Rac simultaneously, can influence Actin muscle as cytoskeleton, also can influence some kinase whose signal transduction paths.(The Journal OF Biological Chemistry1997 Vol272; No50; Dec12 31230-31234) is illustrated as Ra1BP1210 355 403 500 647

CDC42/Rac?GAP Ra1?binding Reps?binding

Reps1 is the one of conjugated protein of Ra1BP1, and according to research, it comprises an EH functional domain (Epshomology domain), a SH3 functional domain and a Ra1BP1 land.Result of study shows that Reps1 and Ra1BP1 can form stabilized complex in cell.(The?Journal?OF?Biological?Chemistry1997?Vol272；No50；Dec12?31230-31234)

Be illustrated as Reps1237 298 599 743

EH?SH3?binding Ra1BP1?binding

EH functional domain (Eps homology domain) is one of Eukaryotic signal cog region, it can distinguish the albumen that contains Asn-Pro-Phe (NPF) sequence, Spectrum Analysis according to the heteronuclear mr, the architecture basics of EH functional domain is a pair of EF chiral structure, and this structure makes the EH functional domain play regulating and controlling effect in processes such as protein-interacting, growth factor signal transmission.(Science?1998?Aug28；281(5381):1357-60)

Reps1 and SH3 functional domain albumen have interaction, and Reps1 is had SH3 in conjunction with activity by supposition, and at the P-A-V-P-P-R of the Reps1 amino acid 531-540 position of having found, this structure is considered to and can combines with the SH3 of Crk and Grb2.Reps1 can form mixture with the EGF acceptor, but concrete process be not clear by joining suitable PROTEIN C rk and Grb2.(The?Journal?OF?Biological?Chemistry?1997?Vol272；No50；Dec12?31230-31234)

EGF can induce the tyrosine phosphorylation of Eps, and we infer that EGF can induce the tyrosine phosphorylation of Reps1 equally, and result of experiment has proved this point.(The?Journal?OF?Biological?Chemistry1997?Vol272；No50；Dec12?31230-31234)

Reps1 can regulate the function of Ra1BP1, thus the proteic expression of Ra1 in the indirect adjustments and controls born of the same parents.Therefore, Reps1 can regulate and control the expression amount of GTP in born of the same parents, thereby influences a lot of aspects of vital movement; Reps1 can have effect to protein-interacting, somatomedin conduction etc.; Reps1 can influence Actin muscle as cytoskeleton; Reps1 also can influence some kinase whose signal transmission; Reps1 can also have interaction with EGF.

According to amino acid homology result relatively, polypeptide of the present invention is accredited as human Ra 1 BPI related protein 82 (HReps82) by deduction.

Homologous protein of the present invention is cloned, is the Reps1 of house mouse, and its length is 744 amino acid, and albumen number is AF031939.

An object of the present invention is to provide isolating new polypeptide-human Ra1BP1 related protein 82 with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of this polypeptide of coding.

Another object of the present invention provides the recombinant vectors of the polynucleotide that contain the human Ra 1 BPI related protein 82 of encoding.

Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain the human Ra 1 BPI related protein 82 of encoding.

Another object of the present invention provides the method for producing human Ra 1 BPI related protein 82.

Another object of the present invention provides the antibody at polypeptide-human Ra1BP1 related protein 82 of the present invention.

Another object of the present invention has provided simulated compound, antagonist, agonist, the inhibitor at polypeptide-human RalBP1 related protein 82 of the present invention.

Another object of the present invention provides the method for the diagnoses and treatment disease relevant unusually with human Ra 1 BPI related protein 82.

In a first aspect of the present invention, novel isolated human Ra 1 BPI related protein 82 is provided, this polypeptide is the people source, and it comprises: have the polypeptide of SEQ ID NO:2 aminoacid sequence or its conservative property variation polypeptide or its active fragments or its reactive derivative, analogue.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.

In a second aspect of the present invention, the polynucleotide of isolating these polypeptide of coding are provided, these polynucleotide comprise a nucleotide sequence, and this nucleotide sequence is shown at least 95% homogeny with a kind of nucleotides sequence that is selected from down group: (a) polynucleotide of the above-mentioned human Ra 1 BPI related protein 82 of coding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, this polynucleotide encoding has the polypeptide of aminoacid sequence shown in the SEQ ID NO:2.More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 94-2328 position among the SEQ ID NO:1; (b) has the sequence of 1-2520 position among the SEQ ID NO:1.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating human Ra 1 BPI related protein 82 " is meant that human Ra 1 BPI related protein 82 is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying human Ra 1 BPI related protein 82 of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of human Ra 1 BPI related protein 82 polypeptide can be used amino acid sequence analysis.

The invention provides a kind of new polypeptide-human Ra1BP1 related protein 82, it is made up of the aminoacid sequence shown in the SEQ IDNO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises fragment, derivative and the analogue of human Ra 1 BPI related protein 82.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep identical biological function of human Ra 1 BPI related protein 82 of the present invention or active polypeptide basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) is a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.

The invention provides isolating nucleic acid (polynucleotide), substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 2520 bases, and its open reading frame (94---2328) 744 amino acid of having encoded.Find relatively that according to amino acid sequence homologous the Reps1 of this polypeptide and house mouse has 94% homology, deducibility goes out the similar 26S Proteasome Structure and Function of Reps1 that this new human Ra 1 BPI related protein 82 has house mouse.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.

The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.

The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, the length of " nucleic acid fragment " contain 10 Nucleotide at least, better are 20-30 Nucleotide at least, are more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding human Ra 1 BPI related protein 82.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

The special polynucleotide sequence of coding human Ra 1 BPI related protein 82 of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.

Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration human Ra 1 BPI related protein 82; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect the protein product of human Ra 1 BPI related protein 82 genetic expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.

Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and with carrier of the present invention or directly with the host cell of human Ra 1 BPI related protein 82 encoding sequence through the genetically engineered generation, and the method that produces polypeptide of the present invention through recombinant technology.

Among the present invention, the polynucleotide sequence of coding human Ra 1 BPI related protein 82 can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.

Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains the human Ra 1 BPI related protein 82 of encoding and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, aLaboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The PL promotor of lambda particles phage; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.

Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.

Among the present invention, the polynucleotide of coding human Ra 1 BPI related protein 82 or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.

Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.

By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce human Ra 1 BPI related protein 82 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:

(1). with the polynucleotide (or varient) of coding of the present invention people human Ra 1 BP 1 related protein 82, or with the recombinant expression vector that contains these polynucleotide proper host cell that transforms or transduce;

(2). in suitable medium, cultivate host cell;

(3). separation, protein purification from substratum or cell.

In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.

The function that polypeptide-human Ra1BP1 related protein 82 of the present invention (HReps82) can be used for regulating Ra1BP1, and the proteic expression of Ra1 in can the indirect adjustments and controls born of the same parents, thus a lot of aspects of organism influenced.Such as, Reps1 can regulate and control the expression amount of GTP in born of the same parents, thus the energy that influences vital movement provides; Reps1 can have effect to protein-interacting, somatomedin conduction etc.; Reps1 can influence Actin muscle as cytoskeleton; Reps1 also can influence some kinase whose signal transmission; Reps1 can also have interaction with EGF.

According to polypeptide of the present invention vital role in vivo, this polypeptide can be used for the treatment of and comprise malignant tumour, immunological disease, and people's acquired immune deficiency syndrome (AIDS), endocrine system disease, nervous system disorders is in interior a lot of diseases.

Polypeptide of the present invention can be used for treating people's malignant tumour, includes but not limited to cancer of the stomach, liver cancer, large bowel cancer, mammary cancer, lung cancer, prostate cancer, cervical cancer, carcinoma of the pancreas, esophagus cancer.

Polypeptide of the present invention is a kind of immunomodulator, has immunological enhancement or immunosuppressive action.Polypeptide of the present invention can be used for the treatment of some diseases, and these diseases comprise immunoreactive anergy, or abnormal immune reaction, or the host defend invalid.Polypeptide of the present invention and its antibody also have effect to damage, defective or the imbalance class disease of immuning tissue, particularly for disease of hematopoietic system (as pernicious anemia), tetter (as psoriasis), autoimmune disease (as rheumatoid arthritis), radiation disease and immune lymphocytic generation and adjusting have extremely close relation.

Polypeptide of the present invention can be used for treating disease in the blood system, as leukemia, lymphopathy, the bad syndromes of myelosis, aplastic anemia, multiple row myelopathy, bleeding property anaemia or the like.

The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of (antagonist) human Ra 1 BPI related protein 82.Agonist improves human Ra 1 BPI related protein 82 biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can in the presence of medicine, the film preparation of mammalian cell or expression human Ra 1 BPI related protein 82 be cultivated with the human Ra 1 BPI related protein 82 of mark.Measure the medicine raising then or check this interactional ability.

The antagonist of human Ra 1 BPI related protein 82 comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of human Ra 1 BPI related protein 82 can combine and eliminate its function with human Ra 1 BPI related protein 82, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.

In screening during as the compound of antagonist, human Ra 1 BPI related protein 82 can be added during bioanalysis measures, by measuring compound interactional influence between human Ra 1 BPI related protein 82 and its acceptor is determined whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with human Ra 1 BPI related protein 82 bonded peptide molecule obtains.During screening, generally tackle the human Ra 1 BPI related protein 82 molecule and carry out mark.

The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at the human Ra 1 BPI related protein 82 antigenic determinant.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

The method of the available human Ra 1 BPI related protein 82 direct injection of the production of polyclonal antibody immune animal (as rabbit, mouse, rat etc.) obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of monoclonal antibody of preparation human Ra 1 BPI related protein 82 include but not limited to hybridoma technology (Kohler and Milstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-human Ra 1 BPI related protein 82.

The antibody of anti-human Ra 1 BPI related protein 82 can be used in the immunohistochemistry technology, detects the human Ra 1 BPI related protein 82 in the biopsy specimen.

With the also available labelled with radioisotope of human Ra 1 BPI related protein 82 bonded monoclonal antibody, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of human Ra 1 BPI related protein 82 high-affinity can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing the human Ra 1 BPI related protein 82 positive cells.

The disease that antibody among the present invention can be used for treating or prevention is relevant with human Ra 1 BPI related protein 82.The antibody that gives suitable dosage can stimulate or block the generation or the activity of human Ra 1 BPI related protein 82.

The invention still further relates to the diagnostic testing process of quantitative and detection and localization human Ra 1 BPI related protein 82 level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The human Ra 1 BPI related protein 82 level that is detected in the test can be with laying down a definition the importance of human Ra 1 BPI related protein 82 in various diseases and be used to the disease of diagnosing human Ra 1 BPI related protein 82 to work.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.

The polynucleotide of coding human Ra 1 BPI related protein 82 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of human Ra 1 BPI related protein 82 or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the human Ra 1 BPI related protein 82 of expressing variation, to suppress endogenic human Ra 1 BPI related protein 82 activity.For example, a kind of human Ra 1 BPI related protein 82 of variation can be the human Ra 1 BPI related protein 82 that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of human Ra 1 BPI related protein 82 expression or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding human Ra 1 BPI related protein 82 are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding human Ra 1 BPI related protein 82 is found in existing document (Sambrook, et al.).The polynucleotide of reorganization coding human Ra 1 BPI related protein 82 can be packaged in the liposome and be transferred in the cell in addition.

Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Suppress the oligonucleotide (comprising sense-rna and DNA) of human Ra 1 BPI related protein 82 mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

The polynucleotide of coding human Ra 1 BPI related protein 82 can be used for the diagnosis with the relative disease of human Ra 1 BPI related protein 82.The unconventionality expression of the expression that the polynucleotide of coding human Ra 1 BPI related protein 82 can be used for detecting human Ra 1 BPI related protein 82 human Ra 1 BPI related protein 82 whether or under morbid state.As the dna sequence dna of the human Ra 1 BPI related protein 82 of encoding can be used for biopsy specimen is hybridized to judge the expression situation of human Ra 1 BPI related protein 82.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect human Ra 1 BPI related protein 82 with the special primer of human Ra 1 BPI related protein 82.

The sudden change that detects the human Ra 1 BPI related protein 82 gene also can be used for the disease of diagnosing human Ra 1 BPI related protein 82 relevant.The form of human Ra 1 BPI related protein 82 sudden change comprises that the point mutation compared with normal wild type human Ra 1 BPI related protein 82 dna sequence dna, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Human Ra 1 BPI related protein 82 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to patient's human Ra 1 BPI related protein 82 will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.

Fig. 1 is the amino acid sequence homology comparison diagram of the Reps1 of human Ra 1 BPI related protein 82 of the present invention and house mouse.The top sequence is a human Ra 1 BPI related protein 82, and the below sequence is the Reps1 of house mouse.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".

Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating human Ra 1 BPI related protein 82.82kDa is proteinic molecular weight.The arrow indication is isolated protein band.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Embodiment 1: the clone of people Ra1BPl related protein 82

Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 0837a06 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 0837a06 clone is 2520bp (shown in Seq ID NO:1), from 94bp to 2328bp the open reading frame (ORF) of a 2235bp, the new protein (shown in Seq ID NO:2) of encoding arranged.We are with this clone's called after p3S-0837a06, encoded protein matter called after human Ra 1 BPI related protein 82.Embodiment 2:cDNA clone's homology retrieval

With the sequence and the encoded protein sequence thereof of human Ra 1 BPI related protein 82 of the present invention, with B1ast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with human Ra 1 BPI related protein 82 homology of the present invention is the Reps1 of a kind of known house mouse, and its encoded protein number is AF031939 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 94%; Similarity is 96%.Embodiment 3: with the gene of RT-PCR method clones coding human Ra 1 BPI related protein 82

Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:

Primer1:5′-GACATTGAGAGCACCAAGAAGGTG-3′(SEQ?ID?NO:3)

Primer2:5′-CCATCCTGACCTTTTTATTGTCGA-3′(SEQ?ID?NO:4)

Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;

Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.

The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/L Tris-Cl, (pH8.5), 1.5mmol/L MgCl ₂, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-2520bp shown in the SEQ ID NO:1 are identical.Embodiment 4:Northern blotting is analyzed the human Ra 1 BPI related protein 82 expression of gene:

Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ gRNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- ³²P dATP prepares by random priming ³²The dna probe of p-mark.Used dna probe is the human Ra 1 BPI related protein 82 coding region sequence (94bp to 2328bp) of pcr amplification shown in Figure 1.Probe (about 2 * 10 with the 32P-mark ⁶Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH ₂PO ₄(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.Embodiment 5: vivoexpression, separation and the purifying of reorganization human Ra 1 BPI related protein 82

According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:

Primer3:5′-CCCCATATGATGGAGCTTTGTGGTGCAACAAGAC-3′(Seq?ID?No:5)

Primer4:5′-CCCGAATTCTTATAGGTGAGAGAATGGTCGAAG-3′?(Seq?ID?No:6)

5 ' end of these two sections primers contains Nde I and EcoR I restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, Nde I and EcoR I restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-0837a06 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-0837a06 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with Nde I and EcoR I, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-0837a06) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-0837a06) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein human Ra 1 BPI related protein 82 of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 82kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.Embodiment 6 anti-human Ra 1 BPI related protein 82 production of antibodies

Synthesize the specific polypeptide of following human Ra 1 BPI related protein 82 with Peptide synthesizer (PE company product):

NH2-Met-Glu-Leu-Cys-Gly-Ala-Thr-Arg-Leu-Gly-Tyr-Phe-Gly-Arg-Ser-COOH(SEQ?ID?NO:7)。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with human Ra 1 BPI related protein 82 specifically.

Sequence table

(1) general information:

(ⅱ) denomination of invention: human Ra 1 BPI related protein 82 and encoding sequence thereof

(ⅲ) sequence number: 7

(2) information of SEQ ID NO:1:

(ⅰ) sequence signature:

(A) length: 2520bp

(B) type: nucleic acid

(C) chain: two strands

(D) topological framework: linearity

(ⅱ) molecule type: cDNA

( ⅹⅰ ) ：SEQ ID NO:1: 1 GACATTGAGAGCACCAAGAAGGTGGTGGTCAACGGGCGGGTGCTGGAGCTGTTCCGGGCC 61 GCGCAGCTGCCGAACGACGTGGTCCTACAGATCATGGAGCTTTGTGGTGCAACAAGACTT121 GGTTATTTTGGAAGAAGTCAGTTCTACATTGCTTTGAAACTTGTAGCTGTTGCCCAGTCT181 GGTTTCCCTTTAAGAGTGGAAAGTATAAATACAGTAAAGGACCTTCCTCTGCCAAGATTT241 GTTGCTTCAAAGAATGAACAGGAATCTCGCCATGCAGCCTCATATTCTTCAGATTCTGAA301 AATCAAGGGTCGTATTCTGGTGTAATTCCCCCACCACCTGGCAGGGGGCAAGTGAAAAAG361 GGATCCGTAAGCCATGATACGGTTCAGCCTCGTACATCTGCAGATGCACAGGAACCTGCA421 TCCCCAGTAGTTTCACCACAGCAATCCCCACCAACTTCTCCACACACATGGAGGAAGCAC481 AGCCGTCATCCCAGCGGTGGGAATAGTGAGAGGCCTCTCGCGGGACCTGGGCCATTTTGG541 TCTCCCTTTGGTGAAGCACAATCAGGTTCTTCTGCTGGTGATGCAGTGTGGTCAGGGCAT601 TCCCCACCTCCACCTCAAGAAAACTGGGTCAGTTTTGCAGATACTCCACCAACCAGTACT661 CTTTTAACCATGCATCCTGCTTCTGTCCAGGACCAGACAACAGTACGAACTGTAGCATCA721 GCTACAACTGCCATTGAAATTCGTAGGCAATCCAGTAGTTATGATGATCCCTGGAAAATA781 ACAGATGAACAAAGACAGTATTATGTAAATCAGTTTAAAACCATTCAGCCTGATCTAAAC841 GGATTTATTCCAGGATCTGCAGCTAAAGAGTTTTTTACAAAATCAAAACTTCCTATTCTT901 GAACTTTCTCATATTTGGGAACTCTCAGACTTTGATAAAGATGGTGCATTGACACTGGAT 961 GAGTTTTGTGCTGCTTTTCATCTGGTGGTTGCTAGGAAGAATGGCTATGATTTACCAGAA1021 AAACTTCCTGAAAGCTTAATGCCCAAACTGATTGATTTGGAAGATTCAGCAGATGTTGGG1081 GATCAGCCAGGTGAGGTAGGTTATTCAGGCTCTCCTGCTGAAGCTCCTCCAAGCAAGTCA1141 CCATCGATGCCATCACTAAACCAGACATGGCCTGAGCTGAATCAGAGCAGTGAGCAGTGG1201 GAGACATTTAGTGAACGCTCTTCAAGCTCACAAACTCTGACCCAATTTGATTCTAACATT1261 GCACCAGCTGATCCTGATACTGCTATTGTTCATCCAGTTCCCATTCGTATGACTCCAAGC1321 AAAATCCACATGCAGGAAATGGAACTTAAAAGAACTGGCAGCGATCATACAAATCCCACT1381 AGCCCATTACTTGTGAAACCATCTGACCTTTTAGAAGAAAATAAGATAAATTCATCGGTG1441 AAATTCGCTTCTGGTAATACTGTAGCAGATGGTTACAGTAGTTCAGACTCTTTTACTTCT1501 GACCCAGAACAGATCGGGAGCAATGTAACTCGTCAAAGGTCTCATTCAGGAACGTCGCCT1561 GATAACACTGCACCACCACCTCCCCCTCCAAGGCCACAGCCCTCTCATTCTAGATCATCA1621 TCTTTAGATATGAATCGGACCTTTACAGTCACCACAGGACAACAACAGGCTGGAGTTGTT1681 GCCCATCCTCCTGCAGTGCCTCCAAGACCACAGCCCTCACAGGCTCCTGGTCCTGCTGTC1741 CATCGCCCAGTGGATGCCGATGGCCTCATAACTCACACTAGTACCTCACCTCAGCAGATA1801 CCAGAGCAACCAAATTTTGTAGATTTCAGTCAGTTTGAAGTATTTGCTGCATCAAATGTA1861 AACGACGAACAAGATGATGAAGCCGAGAAACATCCAGAAGTCCTGCCGGCTGAAAAAGCT1921 TCTGATCCTGCAAGTTCTCTTCGAGTTGCCAAAACAGATAGTAAAACTGAAGAAAAGACA1981 GCTGCTAGTGCTCCTGCCAATGTGAGCAAAGGCACAACACCACTTGCTCCACCACCTAAA2041 CCTGTTCGAAGAAGATTAAAATCAGAAGATGAATTAAGGCCAGAAGTTGATGAACATACA2101 CAAAAGACGGGTGTCTTAGCTGCTGTTCTTGCATCACAACCTTCTATTCCCAGATCTGTT2161 GGGAAAGATAAGAAAGCTATTCAGGCATCAATTAGACGTAATAAGGAAACCAACACCGTT2221 TTGGCCAGATTGAATAGCGAATTGCAGCAACAATTAAAGGATGTTCTTGAGGAGAGAATT2281 TCCCTGGAAGTTCAACTGGAACAACTTCGACCATTCTCTCACCTATAAGCCAATTGCCGT2341 TAACTGTGAACATACTTGTTTTTAAGTGGTTTTGGGTTCAAAGCCAATTTGGAGACCTAG2401 ACATTCAGCTCACTGCTTAACTCAACATTAAATTTTATGATTCTGTTTTGCCCTATATGT2461 TCACCGTTGTATTTAAGTATCTTTTATTTTTTAATTTCGACAATAAAAAGGTCAGGATGG

(2) information of SEQ ID NO:2:

(ⅰ) sequence signature:

(A) length: 744 amino acid

(B) type: amino acid

(D) topological framework: linearity

(ⅱ) molecule type: polypeptide

( ⅹⅰ ) ：SEQ ID NO:2: 1 Met Glu Leu Cys Gly Ala Thr Arg Leu Gly Tyr Phe Gly Arg Ser 16 Gln Phe Tyr Ile Ala Leu Lys Leu Val Ala Val Ala Gln Ser Gly 31 Phe Pro Leu Arg Val G1u Ser Ile Asn Thr Val Lys Asp Leu Pro 46 Leu Pro Arg Pbe Val Ala Ser Lys Asn Glu Gln Glu Ser Arg His 61 Ala Ala Ser Tyr Ser Ser Asp Ser Glu Asn Gln Gly Ser Tyr Ser 76 Gly Val Ile Pro Pro Pro Pro Gly Arg Gly Gln Val Lys Lys Gly 91 Ser Val Ser His Asp Thr Val Gln Pro Arg Thr Ser Ala Asp Ala106 Gln Glu Pro Ala Ser Pro Val Val Ser Pro Gln Gln Ser Pro Pro121 Thr Ser Pro His Thr Trp Arg Lys His Ser Arg His Pro Ser Gly136 Gly Asn Ser Glu Arg Pro Leu Ala Gly Pro Gly Pro Phe Trp Ser151 Pro Phe Gly Glu Ala Gln Ser Gly Ser Ser Ala Gly Asp Ala Val166 Trp Ser Gly His Ser Pro Pro Pro Pro Gln Glu Asn Trp Val Ser181 Pbe Ala Asp Thr Pro Pro Thr Ser Thr Leu Leu Thr Met His Pro196 Ala Ser Val Gln Asp Gln Thr Thr Val Arg Thr Val Ala Ser Ala211 Thr Thr Ala Ile Glu Ile Arg Arg Gln Ser Ser Ser Tyr Asp Asp226 Pro Trp Lys Ile Thr Asp Glu Gln Arg Gln Tyr Tyr Val Asn Gln241 Phe Lys Thr Ile Gln Pro Asp Leu Asn Gly Phe Ile Pro Gly Ser256 Ala Ala Lys Glu Phe Phe Thr Lys Ser Lys Leu Pro Ile Leu Glu271 Leu Ser Hls lle Trp Glu Leu Ser Asp Phe Asp Lys Asp Gly Ala286 Leu Thr Leu Asp Glu Phe Cys Ala Ala Phe His Leu Val Val Ala301 Arg Lys Asn Gly Tyr Asp Leu Pro Glu Lys Leu Pro Glu Ser Leu316 Met Pro Lys Leu Ile Asp Leu Glu Asp Ser Ala Asp Val Gly Asp331 Gln Pro Gly Glu Val Gly Tyr Ser Gly Ser Pro Ala Glu Ala Pro346 Pro Ser Lys Ser Pro Ser Met Pro Ser Leu Asn Gln Thr Trp Pro361 Glu Leu Asn Gln Ser Ser Glu Gln Trp Glu Thr Phe Ser Glu Arg376 Ser Ser Ser Ser Gln Thr Leu Thr Gln Phe Asp Ser Asn lle Ala391 Pro Ala Asp Pro Asp Thr Ala Ile Val His Pro Val Pro Ile Arg406 Met Thr Pro Ser Lys Ile His Met Gln Glu Met Glu Leu Lys Arg421 Thr Gly Ser Asp His Thr Asn Pro Thr Ser Pro Leu Leu Val Lys436 Pro Ser Asp Leu Leu Glu Glu Asn Lys Ile Asn Ser Ser Val Lys451 Phe Ala Ser Gly Asn Thr Val Ala Asp Gly Tyr Ser Ser Ser Asp466 Ser Phe Thr Ser Asp Pro Glu Gln Ile Gly Ser Asn Val Thr Arg481 Gln Arg Ser His Ser Gly Thr Ser Pro Asp Asn Thr Ala Pro Pro496 Pro Pro Pro Pro Arg Pro Gln Pro Ser His Ser Arg Ser Ser Ser511 Leu Asp Met Asn Arg Thr Phe Thr Val Thr Thr Gly Gln Gln Gln526 Ala Gly Val Val Ala His Pro Pro Ala Val Pro Pro Arg Pro Gln541 Pro Ser Gln Ala Pro Gly Pro Ala Val His Arg Pro Val Asp Ala556 Asp Gly Leu Ile Thr His Thr Ser Thr Ser Pro Gln Gln Ile Pro571 Glu Gln Pro Asn Phe Val Asp Phe Ser Gln Phe Glu Val Phe Ma586 Ala Ser Asn Val Asn Asp Glu Gln Asp Asp Glu Ala Glu Lys His601 Pro Glu Val Leu Pro Ala Glu Lys Ala Ser Asp Pro Ala Ser Ser616 Leu Arg Val Ala Lys Thr Asp Ser Lys Thr Glu Glu Lys Thr Ala631 Ala Ser Ala Pro Ala Asn Val Ser Lys Gly Thr Thr Pro Leu Ala646 Pro Pro Pro Lys Pro Val Arg Arg Arg Leu Lys Ser Glu Asp Glu661 Leu Arg Pro Glu Val Asp Glu His Thr Gln Lys Thr Gly Val Leu676 Ala Ala Val Leu Ala Ser Gln Pro Ser Ile Pro Arg Ser Val Gly691 Lys Asp Lys Lys Ala Ile Gln Ala Ser Ile Arg Arg Asn Lys Glu706 Thr Asn Thr Val Leu Ala Arg Leu Asn Ser Glu Leu Gln Gln Gln721 Leu Lys Asp Val Leu Glu Glu Arg Ile Ser Leu Glu Val Gln Leu736 Glu Gln Leu Arg Pro Phe Ser His Leu

(2) information of SEQ ID NO:3

(ⅰ) sequence signature

(A) length: 24 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide

(ⅹ ⅰ) sequence description: SEQ ID NO:3:

5′-GACATTGAGAGCACCAAGAAGGTG-3′ 24

(2) information of SEQ ID NO:4

(ⅰ) sequence signature

(A) length: 24 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide

(ⅹ ⅰ) sequence description: SEQ ID NO:4:

5′-CCATCCTGACCTTTTTATTGTCGA-3′ 24

(6) information of SEQ ID NO:5

(ⅰ) sequence signature

(A) length: 34 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide

(ⅹ ⅰ) sequence description: SEQ ID NO:5:

5′-CCCCATATGATGGAGCTTTGTGGTGCAACAAGAC-3′ 34

(7) information of SEQ ID NO:6

(ⅰ) sequence signature

(A) length: 33 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide

(ⅹ ⅰ) sequence description: SEQ ID NO:6:

5′-CCCGAATTCTTATAGGTGAGAGAATGGTCGAAG-3′EcoRⅠ 33

(8) information of SEQ ID NO:7:

(ⅰ) sequence signature:

(A) length: 15 amino acid

(B) type: amino acid

(D) topological framework: linearity

(ⅱ) molecule type: polypeptide

(ⅹ ⅰ) sequence description: SEQ ID NO:7:

NH2-Met-Glu-Leu-Cys-Gly-Ala-Thr-Arg-Leu-Gly-Tyr-Phe-Gly-Arg-Ser-COOH

Claims (18)

1, a kind of isolated polypeptide-human Ra 1 BPI related protein 82 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ ID NO:2 or active fragments, analogue or the derivative of its polypeptide.

2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in the SEQ ID NO:2.

3, polypeptide as claimed in claim 2 is characterized in that it comprises the polypeptide with the aminoacid sequence shown in the SEQ ID NO:2.

4, a kind of isolating polynucleotide is characterized in that described polynucleotide comprise to be selected from down a kind of in the group: (a) coding has the polynucleotide of the polypeptide of aminoacid sequence shown in the SEQ ID NO:2 or its fragment, analogue, derivative; (b) with polynucleotide (a) complementary polynucleotide; Or (c) and (a) or the polynucleotide of at least 95% homogeny (b) are arranged.

5, polynucleotide as claimed in claim 4 is characterized in that described polynucleotide comprise the polynucleotide that coding has aminoacid sequence shown in the SEQ ID NO:2.

6, polynucleotide as claimed in claim 4, the sequence that it is characterized in that described polynucleotide include the sequence of 1-2520 position among the sequence of 94-2328 position among the SEQ IDNO:1 or the SEQ ID NO:1.

7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.

8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:

(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or

(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.

9, a kind of preparation method with the active polypeptide of human Ra 1 BPI related protein 82 is characterized in that described method comprises:

(a) expressing under the human Ra 1 BPI related protein 82 condition, cultivate the described through engineering approaches host cell of claim 8;

(b) from culture, isolate and have the active polypeptide of human Ra 1 BPI related protein 82.

10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with human Ra 1 BPI related protein 82 specificity bonded antibody.

11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses human Ra 1 BPI related protein 82.

12, compound as claimed in claim 11 is characterized in that it is the polynucleotide sequence shown in the SEQ ID NO:1 or its segmental antisense sequences.

13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used to regulate human Ra 1 BPI related protein 82 in vivo, the method for external activity.

14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.

15, as the application of polypeptide as described in the arbitrary claim among the claim 1-3, it is characterized in that it is applied to screen the stand-in of human Ra 1 BPI related protein 82, agonist, antagonist or inhibitor; Perhaps be used for the peptide finger print identification.

16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.

17,, it is characterized in that forming pharmaceutical composition with safe and effective dosage and pharmaceutically acceptable carrier as diagnosis or the treatment disease relevant unusually with human Ra 1 BPI related protein 82 with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.

18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11, it is characterized in that being used for the treatment of as malignant tumour with described polypeptide, polynucleotide or compound, hemopathy, the medicine of HIV infection and immunological disease and all kinds of inflammation.

Images